U.S.C. homeSearch U.S. Code
U.S. CodeTitle 21Chapter 9— Federal Food, Drug, And Cosmetic ActSubchapter VII— General AuthorityPart A— General Administrative Provisions

21 U.S.C. § 372 (2026)

Examinations and investigations

Edition and currency
U.S. Code current through Pub. L. 119-102 (OLRC release point). The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTU.S. Code current through Pub. L. 119-102 (OLRC release point) cited 1944–2025 51citing cases
At a glance

Courts have cited this section in 51 opinions since 1944, 2 of them in the last five years.

(a) Authority to conduct(1)(A) The Secretary is authorized to conduct examinations and investigations for the purposes of this chapter through officers and employees of the Department or through any health, food, or drug officer or employee of any State, Territory, or political subdivision thereof, duly commissioned by the Secretary as an officer of the Department.(B)(i) For a tobacco product, to the extent feasible, the Secretary shall contract with the States in accordance with this paragraph to carry out inspections of retailers within that State in connection with the enforcement of this chapter.(ii) The Secretary shall not enter into any contract under clause (i) with the government of any of the several States to exercise enforcement authority under this chapter on Indian country without the express written consent of the Indian tribe involved.(2)(A) In addition to the authority established in paragraph (1), the Secretary, pursuant to a memorandum of understanding between the Secretary and the head of another Federal department or agency, is authorized to conduct examinations and investigations for the purposes of this chapter through the officers and employees of such other department or agency, subject to subparagraph (B). Such a memorandum shall include provisions to ensure adequate training of such officers and employees to conduct the examinations and investigations. The memorandum of understanding shall contain provisions regarding reimbursement. Such provisions may, at the sole discretion of the head of the other department or agency, require reimbursement, in whole or in part, from the Secretary for the examinations or investigations performed under this section by the officers or employees of the other department or agency.(B) A memorandum of understanding under subparagraph (A) between the Secretary and another Federal department or agency is effective only in the case of examinations or inspections at facilities or other locations that are jointly regulated by the Secretary and such department or agency.(C) For any fiscal year in which the Secretary and the head of another Federal department or agency carries out one or more examinations or inspections under a memorandum of understanding under subparagraph (A), the Secretary and the head of such department or agency shall with respect to their respective departments or agencies submit to the committees of jurisdiction (authorizing and appropriating) in the House of Representatives and the Senate a report that provides, for such year—(i) the number of officers or employees that carried out one or more programs, projects, or activities under such memorandum;(ii) the number of additional articles that were inspected or examined as a result of such memorandum; and(iii) the number of additional examinations or investigations that were carried out pursuant to such memorandum.(3) In the case of food packed in the Commonwealth of Puerto Rico or a Territory the Secretary shall attempt to make inspection of such food at the first point of entry within the United States when, in his opinion and with due regard to the enforcement of all the provisions of this chapter, the facilities at his disposal will permit of such inspection.(4) For the purposes of this subsection, the term “United States” means the States and the District of Columbia.(b) Availability to owner of part of analysis samples

Where a sample of a food, drug, or cosmetic is collected for analysis under this chapter the Secretary shall, upon request, provide a part of such official sample for examination or analysis by any person named on the label of the article, or the owner thereof, or his attorney or agent; except that the Secretary is authorized, by regulations, to make such reasonable exceptions from, and impose such reasonable terms and conditions relating to, the operation of this subsection as he finds necessary for the proper administration of the provisions of this chapter.

(c) Records of other departments and agencies

For purposes of enforcement of this chapter, records of any department or independent establishment in the executive branch of the Government shall be open to inspection by any official of the Department duly authorized by the Secretary to make such inspection.

(d) Information on patents for drugs

The Secretary is authorized and directed, upon request from the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, to furnish full and complete information with respect to such questions relating to drugs as the Director may submit concerning any patent application. The Secretary is further authorized, upon receipt of any such request, to conduct or cause to be conducted, such research as may be required.

(e) Powers of enforcement personnelAny officer or employee of the Department designated by the Secretary to conduct examinations, investigations, or inspections under this chapter relating to counterfeit drugs may, when so authorized by the Secretary—(1) carry firearms;(2) execute and serve search warrants and arrest warrants;(3) execute seizure by process issued pursuant to libel under section 334 of this title;(4) make arrests without warrant for offenses under this chapter with respect to such drugs if the offense is committed in his presence or, in the case of a felony, if he has probable cause to believe that the person so arrested has committed, or is committing, such offense; and(5) make, prior to the institution of libel proceedings under section 334(a)(2) of this title, seizures of drugs or containers or of equipment, punches, dies, plates, stones, labeling, or other things, if they are, or he has reasonable grounds to believe that they are, subject to seizure and condemnation under such section 334(a)(2). In the event of seizure pursuant to this paragraph (5), libel proceedings under section 334(a)(2) of this title shall be instituted promptly and the property seized be placed under the jurisdiction of the court.(June 25, 1938, ch. 675, § 702, 52 Stat. 1056; Pub. L. 87–781, title III, §§ 307(b), 308, Oct. 10, 1962, 76 Stat. 796; Pub. L. 89–74, § 8(a), July 15, 1965, 79 Stat. 234; Pub. L. 91–513, title II, § 701(f), Oct. 27, 1970, 84 Stat. 1282; Pub. L. 102–300, § 6(b)(2), June 16, 1992, 106 Stat. 240; Pub. L. 103–80, § 3(dd)(2), Aug. 13, 1993, 107 Stat. 779; Pub. L. 106–113, div. B, § 1000(a)(9) [title IV, § 4732(b)(12)], Nov. 29, 1999, 113 Stat. 1536, 1501A–584; Pub. L. 107–188, title III, § 314, June 12, 2002, 116 Stat. 674; Pub. L. 111–31, div. A, title I, § 103(g), June 22, 2009, 123 Stat. 1837.)Editorial NotesAmendments

2009—Subsec. (a)(1). Pub. L. 111–31 designated existing provisions as subpar. (A) and added subpar. (B).

2002—Subsec. (a). Pub. L. 107–188 inserted “(1)” before “The Secretary is authorized to conduct”, added par. (2), inserted “(3)” before “In the case of food packed”, and substituted “(4) For the purposes of this subsection,” for “For the purposes of this subsection”.

1999—Subsec. (d). Pub. L. 106–113, in first sentence, substituted “Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office” for “Commissioner of Patents” and “Director” for “Commissioner”.

1993—Subsec. (c). Pub. L. 103–80 struck out “of Agriculture” after “Department”.

1992—Subsec. (c). Pub. L. 102–300, which directed the amendment of subsec. (c) by striking out “of Health, Education, and Welfare”, could not be executed because such words did not appear in the original statutory text. See 1993 Amendment note above and Transfer of Functions note below.

1970—Subsec. (e). Pub. L. 91–513 struck out reference to depressant or stimulant drugs.

1965—Subsec. (e). Pub. L. 89–74 added subsec. (e).

1962—Subsec. (a). Pub. L. 87–781, § 307(b), inserted “the Commonwealth of Puerto Rico or” before “a Territory the Secretary”.

Subsec. (d). Pub. L. 87–781, § 308, added subsec. (d).

Statutory Notes and Related SubsidiariesEffective Date of 1999 Amendment

Amendment by Pub. L. 106–113 effective 4 months after Nov. 29, 1999, see section 1000(a)(9) [title IV, § 4731] of Pub. L. 106–113, set out as a note under section 1 of Title 35, Patents.

Effective Date of 1970 Amendment

Amendment by Pub. L. 91–513 effective on first day of seventh calendar month that begins after Oct. 26, 1970, see section 704 of Pub. L. 91–513, set out as an Effective Date note under section 801 of this title.

Effective Date of 1965 Amendment

Amendment by Pub. L. 89–74 effective July 15, 1965, see section 11 of Pub. L. 89–74, set out as a note under section 321 of this title.

Savings Provision

Amendment by Pub. L. 91–513 not to affect or abate any prosecutions for any violation of law or any civil seizures or forfeitures and injunctive proceedings commenced prior to the effective date of such amendment, and all administrative proceedings pending before the Bureau of Narcotics and Dangerous Drugs [now Drug Enforcement Administration] on Oct. 27, 1970, to be continued and brought to final determination in accord with laws and regulations in effect prior to Oct. 27, 1970, see section 702 of Pub. L. 91–513, set out as a note under section 321 of this title.

Executive DocumentsTransfer of Functions

For transfer of functions of Federal Security Administrator to Secretary of Health, Education, and Welfare [now Health and Human Services], and of Food and Drug Administration in the Department of Agriculture to Federal Security Agency, see note set out under section 321 of this title.

The 20 cases that cite 21 U.S.C. § 372 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBuckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001).
cites § 372 2×cited by 935 cases
Where it cites § 372
“The FDA is empowered to investigate suspected fraud, see 21 U. S. C. § 372 ; 21 CFR § 5.35 (2000), and citizens may report wrongdoing and petition the agency to take action, § 10.”
The case’s holding
State law claims alleging fraud on the FDA are impliedly preempted by federal law because they interfere with the agency's responsibility to police fraud according to its own objectives.
Later courts cite it for
“the fdca leaves no doubt that it is the federal government rather than private litigants who are authorized to file suit for noncompliance with the medical device provisions.” · 87 citing courts
2
REDAss'n of Irritated Residents v. Env't Prot. Agency, 494 F.3d 1027 (D.C. Cir. 2007).
cites § 372 2×cited by 43 cases
Abrogated by Sierra Club v. Jackson: 2 citing opinions say abrogated.
Where it cites § 372
“In this case, the relevant statutes — the Clean Air Act, CERCLA and EPCRA — describe EPA's authority in similarly permissive terms. The Clean Air Act, for example, states in the primary federal enforcement provision that "whenever, on the basis of any information available to…”
The case’s holding
An agency's decision to defer or forgo enforcement against violators, including through consent agreements, is presumptively committed to agency discretion and unreviewable under the APA.
Later courts cite it for
“give any indication that violators must be pursued in every case, or that one particular enforcement strategy must be chosen over another” · 4 citing courts
3
GREENPhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010).
cites § 372 1×cited by 57 cases
Where it cites § 372
“21 U.S.C. § 372 . The FDCA provides the FDA with a number of enforcement remedies that may be sought.”
The case’s holding
A private Lanham Act action is barred if the claim requires litigation of an underlying Food, Drug, and Cosmetic Act violation that the FDA has not concluded occurred.
Later courts cite it for
“because the fdca forbids private rights of action under that statute, a private action brought under the lanham act may not be pursued when, as here, the claim would require litigation of the alleged underlying fdca violation in a circumstance where the fda has not itself concluded that there was such a violation.” · 11 citing courts
4
GREENLofton v. McNeil Consum. & Specialty Pharm., 672 F.3d 372 (5th Cir. 2012).
cites § 372 1×cited by 52 cases
Where it cites § 372
“Section 262 ), as amended; or (2) the warnings provided were those stated in monographs developed by the United States Food and Drug Administration for pharmaceutical products that may be distributed without an approved new drug application.”
The case’s holding
A state law provision requiring a plaintiff to establish fraud on the FDA to rebut a presumption of non-liability is preempted unless the FDA itself finds fraud.
Later courts cite it for
“under texas law, a drug manufacturer enjoys a rebuttable presumption that it is not liable for failure to warn if the fda has approved 'the warnings or information' accompanying the product alleged to have harmed the plaintiff.” · 5 citing courts
cites § 372 1×cited by 50 cases
Where it cites § 372
“§ 12 (c)(2), which states that “[t]he [CFTC] may, in its discretion * * *, review any decision by an exchange whereby a person is suspended, expelled, otherwise disciplined or denied access to the exchange.”
The case’s holding
An error in a notice of appeal does not result in a loss of the right to appeal if the intent is inferable and the appellee is not misled.
Later courts cite it for
“an error designating the judgment or a part thereof will not result in a loss of appeal if the intent to appeal from the judgment complained of may be inferred from the notice and if the appellee has not been misled by the defect.” · 2 citing courts
cites § 372 1×cited by 20 cases
Where it cites § 372
“2d 714 (1985) (interpreting the term "authorize” in § 372 of the Food, Drug and Cosmetic Act, 21 U.S.C. § 372 ). Further, common usage of the word “authorize” is understood to imply a discretionary delegation of duty.”
Later courts cite it for
“consummated 'agency action' that apa views as final, notwithstanding the fact that the agency 'did' nothing.” · 2 citing courts
7
GREENThorn v. Medtronic Sofamor Danek, USA, Inc., 81 F. Supp. 3d 619 (W.D. Mich. 2015).
cites § 372 1×cited by 20 cases
Where it cites § 372
“2d 854 (2001) (indicating that the FDA is empowered to investigate suspected fraud, see 21 U.S.C. § 372 ; 21 C.F.R. § 5.35 , and citizens may report wrongdoing and petition the agency to take action, § 10.”
Later courts cite it for
“there is no state law duty to abstain from off-label promotion.” · 2 citing courts
8
GREENIn re Sichert, 566 F.2d 1154 (C.C.P.A. 1977).
cites § 372 2×cited by 10 cases
Where it cites § 372
“Moreover, the PTO did not request information or research on appellant’s compositions from the Secretary of Health, Education, and Welfare, which is specifically provided for in 21 U.S.C. § 372 (d). 7 b. Lack of Safety The Solicitor notes that the board did not reverse the…”
Later courts cite it for
“the examiner's conclusory statement that the specification does not teach the best mode of using the invention is unaccompanied by evidence or reasoning and is entirely inadequate to support the rejection.” · 1 citing court
9
GREENStephen Wyden v. Comm'r of Patents & Trademarks, 807 F.2d 934 (Fed. Cir. 1986).
cites § 372 1×cited by 34 cases
Where it cites § 372
“(15) 21 U.S.C. § 372 (access to PTO materials by Food and Drug Administration).”
The case’s holding
An action reviewing a Commissioner's suspension of a patent practitioner under the patent statute arises under an Act of Congress relating to patents, so the Federal Circuit has exclusive appellate jurisdiction.
10
GREENGonzalez v. Bayer Healthcare Pharm., Inc., 930 F. Supp. 2d 808 (S.D. Tex. 2013).
cites § 372 1×cited by 14 cases
Where it cites § 372
“The FDA is responsible for policing fraud and “has the authority to investigate fraud, 21 U.S.C. § 372 , consider citizen petitions, 21 C.”
Later courts cite it for
“while the learned intermediary doctrine shifts the manufacturer's duty to warn from end user to intermediary, the plaintiff's burden of proof remains the same, i.e., to prove the product's warning was inadequate.” · 2 citing courts
11
GREENUnited States v. Roux Labs., Inc., 456 F. Supp. 973 (M.D. Fla. 1978).
cites § 372 2×cited by 9 cases
Where it cites § 372
“The Court will rule on the four issues raised by Roux, and then in a separate order rule on the specific objections raised by Roux. I. FDA’s Authority to Search and Collect Samples 21 U.”
12
GREENZimmerman v. Novartis Pharm. Corp., 889 F. Supp. 2d 757 (D. Md. 2012).
cites § 372 1×cited by 12 cases
Summary
No passage or summary on file for this case yet.
13
GREENEvelyn Falkowski v. Equal Emp. Opportunity Comm'n, 764 F.2d 907 (D.C. Cir. 1985).
cites § 372 1×cited by 19 cases
Where it cites § 372
“In Chaney itself, in contrast, the language at issue was the general provision on enforcement of all parts of the relevant statute, which stated simply that “[t]he Secretary [of Health and Human Services] is authorized to conduct examination and investigations,” 21 U.S.C. § 372…”
Later courts cite it for
“involved the allocation of the agency's scarce legal resources” · 1 citing court
14
GREENBaker v. St. Jude Med., S.C., Inc., 178 S.W.3d 127 (Tex. App.—Houston [1st Dist.] 2005).
cites § 372 1×cited by 7 cases
Where it cites § 372
“As the Court detailed in Buckman , The FDA is empowered to investigate suspected fraud, see 21 U.S.C. § 372 ; 21 CFR § 5.35 (2000), and citizens may report wrongdoing and petition the agency to take action, § 10.”
Later courts cite it for
“claims based on a manufacturer's no. 11-10076 failure to follow the fda's regulations and procedures in manufacturing and marketing a device are not preempted.” · 2 citing courts
15
GREENWright v. Medtronic, Inc., 81 F. Supp. 3d 600 (W.D. Mich. 2015).
cites § 372 1×cited by 7 cases
Where it cites § 372
“2d 854 (2001) *607 (indicating that the FDA is empowered to investigate suspected fraud, see 21 U.S.C. § 372 ; 21 C.F.R. § 5.35 , and citizens may-report wrongdoing and petition the agency to take action, § 10.”
16
GREENWildEarth Guardians v. United States Dep't of Just., 181 F. Supp. 3d 651 (D. Ariz. 2015).
cites § 372 1×cited by 7 cases
Where it cites § 372
“The court distinguished the Cook challenge to the challenge asserted in Heckler , with the difference being that the Heckler plaintiffs relied on the general enforcement provisions of the FDCA, 21 U.S.C.A. § 372 , which “authorized” the Secretary to conduct examinations and…”
Later courts cite it for
“extraordinary circumstances include situations where the claimant has actively pursued 11 his judicial remedies by filing a defective pleading during the statutory period, or where 12 the complainant has been induced or tricked by his adversary's misconduct into allowing 13 the filing deadline to pass.” · 3 citing courts
17
GREENUnited States v. White, 766 F. Supp. 873 (E.D. Wash. 1991).
cites § 372 1×cited by 13 cases
Where it cites § 372
“The sample provision of the Act, 21 U.S.C. § 372 (b), at the time provided: (b) Where a sample of a food, drug, or cosmetic is collected for analysis under this chapter the Administrator shall, upon request, provide a part of such official sample for examination or analysis by…”
18
GREENUnited States v. Gel Spice Co., 601 F. Supp. 1214 (E.D.N.Y. 1985).
cites § 372 1×cited by 12 cases
Where it cites § 372
“20 Since the FDA has already provided the defendants with samples pursuant to 21 U.S.C. § 372 , the only outstanding discovery matter is the production of 16(b) material by the defendants (13).”
19
GREENKobar ex rel. Kobar v. Novartis Corp., 378 F. Supp. 2d 1166 (D. Ariz. 2005).
cites § 372 1×cited by 6 cases
Where it cites § 372
“87 (f) (2000), to investigate suspected fraud, 21 U.S.C. § 372 (2000); 21 C.F.R. § 5.35 (2000), to seek injunctive relief, 21 U.”
Later courts cite it for
“bjoth common law fraud on the fda claim and an immunity statute that requires a plaintiff to prove fraud on the fda in order to collect punitive damages place state courts, as finders of fact, in the uncomfortable and difficult position of having to answer the question of what role, if any, the allegedly withheld information would have played in the fda's complicated approval process.” · 1 citing court
20
GREENIn re Trasylol Prods. Liab. Litig.-MDL-1928, 763 F. Supp. 2d 1312 (S.D. Fla. 2010).
cites § 372 1×cited by 6 cases
Where it cites § 372
“(citing 21 U.S.C. § 372 )) While the FDA approved Bayer’s application to market Trasylol in 1993, it has never determined that Bayer failed to comply with FDCA standards for disclosing information to the agency about Trasylol or that any such non disclosure affected the agency’s…”

Show all 51 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
194419842025

One bar per 2 years. Tallest: 4 cases in 1984–1985. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
9th Cir.5D.D.C.4C.C.P.A.3D. Ariz.24th Cir.25th Cir.27th Cir.2D.C. Cir.2

The 8 courts with the most citing cases, of 32 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 51 citing cases (list view) →

Enactment and amendments
(June 25, 1938, ch. 675, § 702, 52 Stat. 1056; Pub. L. 87–781, title III, §§ 307(b), 308, Oct. 10, 1962, 76 Stat. 796; Pub. L. 89–74, § 8(a), July 15, 1965, 79 Stat. 234; Pub. L. 91–513, title II, § 701(f), Oct. 27, 1970, 84 Stat. 1282; Pub. L. 102–300, § 6(b)(2), June 16, 1992, 106 Stat. 240; Pub. L. 103–80, § 3(dd)(2), Aug. 13, 1993, 107 Stat. 779; Pub. L. 106–113, div. B, § 1000(a)(9) [title IV, § 4732(b)(12)], Nov. 29, 1999, 113 Stat. 1536, 1501A–584; Pub. L. 107–188, title III, § 314, June 12, 2002, 116 Stat. 674; Pub. L. 111–31, div. A, title I, § 103(g), June 22, 2009, 123 Stat. 1837.)
Amendment years (notes): 2009, 2002, 1999, 1993, 1992, 1970, 1965, 1962
Versions

Edition shown: U.S. Code current through Pub. L. 119-102 (OLRC release point). Syfert holds no earlier or later version of this section.

U.S.C. Home  |  Search U.S. Code  |  Search cases for this section  |  syfert.com